Moxifloxacin efficacy againstMycobacterium abscessus in vivousing zebrafish model

Abstract

Moxifloxacin (MFX) showed good activity in vitro against Mycobacterium abscessus (M. abscessus) and was suggested as one of the antibiotic regimens for adults with M. abscessus disease. However, some other studies showed that MFX showed less or none activity against M. abscessus. In our study we aim to evaluate MFX activity against M. abscessus using zebrafish (ZF) model in vivo. MIC of each drugs were determined by broth microdilution method. M. abscessus labeled by CM-DiI, were micro-injected into ZF. Survival curves were determined by recording dead ZF every day. After 4 days of incubation ZF were lysed. Colony-forming unit (CFU) were enumerated and results are expressed as mean log10 CFU per ZF. Bacteria dissemination and fluorescence intensity in ZF were observed and analyzed. Inhibition rate was also calculated. In our study MFX showed good activity in vitro. But in vivo MFX showed limited restriction to M. abscessus. The association between increased survival and high dose of MFX is not significant. Same results were observed in bacterial fluorescence intensity and inhibition rates, with no significant difference when compared with no drug group (P > 0.05). However, significant difference was observed in azithromycin (AZM) group. MFX showed limited efficacy on Mycobacterium abscessus in vivo using ZF model. MFX’s activity in vivo need to be confirmed.

Omadacycline Potentiates Clarithromycin Activity Against Mycobacterium abscessus

“…This new finding was further validated using ZF larvae infected by Mab microinjection into the caudal vein. ZF share a high degree of genetic similarity with humans, and approximately 70% of all human disease genes show functional homologs in ZF (Santoriello and Zon, 2012;Nie et al, 2020). Furthermore, ZF are relatively simple to work with, cost-effective, and have genetic tractability and optical transparency, which allows for very easy and valid research.…”